These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38954904)

  • 21. Corrigendum to "Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis" [Pharmacol. Res. 188 (2023) 106668].
    Lei T; Xu T; Zhang N; Zou X; Kong Z; Wei C; Wang Z
    Pharmacol Res; 2023 Oct; 196():106922. PubMed ID: 37718164
    [No Abstract]   [Full Text] [Related]  

  • 22. Discovery of New Glucose Uptake Inhibitors as Potential Anticancer Agents by Non-Radioactive Cell-Based Assays.
    Hung HC; Li LC; Guh JH; Kung FL; Hsu LC
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36432207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-Target Chemometric Modelling, Fragment Analysis and Virtual Screening with ERK Inhibitors as Potential Anticancer Agents.
    Halder AK; Giri AK; Cordeiro MNDS
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31671605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hierarchical virtual screening approaches in small molecule drug discovery.
    Kumar A; Zhang KY
    Methods; 2015 Jan; 71():26-37. PubMed ID: 25072167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corrigendum to "siRNA: Mechanism of action, challenges, and therapeutic approaches" [Eur. J. Pharmacol. 905 (2021) 174178].
    Alshaer W; Zureigat H; Al Karaki A; Al-Kadash A; Gharaibeh L; Hatmal MM; Aljabali AAA; Awidi A
    Eur J Pharmacol; 2022 Feb; 916():174741. PubMed ID: 34998574
    [No Abstract]   [Full Text] [Related]  

  • 26. Corrigendum to "Human GRIN2B variants in neurodevelopmental disorders" [J Pharmacol Sci 132 (2) 115-121].
    Hu C; Chen W; Myers SJ; Yuan H; Traynelis SF
    J Pharmacol Sci; 2017 Apr; 133(4):280. PubMed ID: 28434657
    [No Abstract]   [Full Text] [Related]  

  • 27. Notice of Concern: Kawas LH, Yamamoto BJ, Wright JW, and Harding JW (2011) Mimics of the Dimerization Domain of Hepatocyte Growth Factor Exhibit Anti-Met and Anticancer Activity,
    J Pharmacol Exp Ther; 2021 Sep; 378(3):312. PubMed ID: 34551988
    [No Abstract]   [Full Text] [Related]  

  • 28. DeepCancerMap: A versatile deep learning platform for target- and cell-based anticancer drug discovery.
    Wu J; Xiao Y; Lin M; Cai H; Zhao D; Li Y; Luo H; Tang C; Wang L
    Eur J Med Chem; 2023 Jul; 255():115401. PubMed ID: 37116265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corrigendum to "Flaccidoside II ameliorates collagen-induced arthritis in mice" [Eur. J. Pharmacol. 880 (2020) 173155].
    Zhang GB; Jia ZJ; Zhang MH; Li YJ; Tian LY; Cheng J
    Eur J Pharmacol; 2021 Apr; 897():173963. PubMed ID: 33674037
    [No Abstract]   [Full Text] [Related]  

  • 30. Retraction: Boldt et al. J Cardiovasc Pharmacol 1989;14 Suppl 1:S50-56, Boldt et al. J Cardiovasc Pharmacol 1990;15(1):37-43, and Boldt et al. J Cardiovasc Pharmacol 1995;25(3):416-423.
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):330. PubMed ID: 34554680
    [No Abstract]   [Full Text] [Related]  

  • 31. Corrigendum to "Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus" [Eur. J. Pharmacol. 728 (5 April 2014) 128-134].
    Patel BM; Raghunathan S; Porwal U
    Eur J Pharmacol; 2023 Sep; 954():175900. PubMed ID: 37451940
    [No Abstract]   [Full Text] [Related]  

  • 32. Corrigendum to "P2Y14 receptor in trigeminal ganglion contributes to neuropathic pain in mice" [Eur. J. Pharmacol. 931 (2022) 175211].
    Lin J; Fang X; Liu F; Zhang Y; Li Y; Fang Z; Tang Q; Li C; Zhou C; Shen J
    Eur J Pharmacol; 2022 Oct; 932():175266. PubMed ID: 36096845
    [No Abstract]   [Full Text] [Related]  

  • 33. Corrigendum to "A novel rat model of contrast-induced nephropathy based on dehydration" [J Pharmacol Sci 141 (2019) 49-55].
    Liu K; Zhou LY; Li DY; Cheng WJ; Yin WJ; Hu C; Xie YL; Wang JL; Zuo SR; Chen LH; Zhou G; Zuo XC
    J Pharmacol Sci; 2020 Jul; 143(3):242. PubMed ID: 32448772
    [No Abstract]   [Full Text] [Related]  

  • 34. Corrigendum to "A new rat model of neonatal bilirubin encephalopathy (kernicterus)" [J. Pharmacol. Toxicol. Methods 84 (2017) 44-50].
    Amini N; Vousooghi N; Soleimani M; Samadikuchaksaraei A; Akbari M; Safakheil H; Atafimanesh P; Shahbazi A; Brouki Milan P; Ramezani S; Mozafari M; Joghataei MT
    J Pharmacol Toxicol Methods; 2018; 92():95. PubMed ID: 29534860
    [No Abstract]   [Full Text] [Related]  

  • 35. Corrigendum to "Tumor suppression effects of myoepithelial cells on mice breast cancer" [Eur. J. Pharmacol. 765 (2015) 171-178].
    Farhangi B; Latifpour M; Alizadeh AM; Khodayari H; Khodayari S; Khaniki M; Ghasempour S
    Eur J Pharmacol; 2016 Jul; 782():119. PubMed ID: 27180042
    [No Abstract]   [Full Text] [Related]  

  • 36. Corrigendum to: An account on the history of pharmacology in Spain [Pharmacol. Res. 202 (2024) 107104 Pages 1-11 https://doi.org/10.1016/j.phrs.2024.107104].
    Aldea-Perona AM; Beledo JF; Frías Iniesta J; García AG; Tamargo J; Zaragozá F
    Pharmacol Res; 2024 Jul; 205():107240. PubMed ID: 38821766
    [No Abstract]   [Full Text] [Related]  

  • 37. Corrigendum to "Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension" [Eur. J. Pharmacol. 943 (2023) 175558].
    Abdulkareem AO; Tiwari P; Lone ZR; Iqbal H; Gupta S; Jha RK; Chanda D; Jagavelu K; Hanif K
    Eur J Pharmacol; 2023 Jul; 950():175750. PubMed ID: 37147146
    [No Abstract]   [Full Text] [Related]  

  • 38. Corrigendum to "Sulfur dioxide derivatives attenuates consolidation of contextual fear memory in mice" [Eur. J. Pharmacol. 914 2021 174658].
    Wang X; Zhao Y; Shi X; Gong M; Hao Y; Fu Y; Velez de-la-Paz OI; Wang X; Du Y; Guo X; Song L; Meng L; Gao Y; Yin X; Wang S; Shi H; Shi Y
    Eur J Pharmacol; 2022 Mar; 918():174794. PubMed ID: 35125204
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to "Restoration of sirt1 function by pterostilbene attenuates hypoxia-reoxygenation injury in cardiomyocytes" [Eur. J. Pharmacol. 776 (2016) 26-33].
    Guo Y; Zhang L; Li F; Hu CP; Zhang Z
    Eur J Pharmacol; 2016 Jul; 782():120. PubMed ID: 27180043
    [No Abstract]   [Full Text] [Related]  

  • 40. A Strategy Combining Differential Low-Throughput Screening and Virtual Screening (DLS-VS) Accelerating the Discovery of new Modulators for the Orphan GPR34 Receptor.
    Diaz C; Labit-Le Bouteiller C; Yvon S; Cambon-Kernëis A; Roasio A; Jamme MF; Aries A; Feuillerat C; Perret E; Guette F; Dieu P; Miloux B; Albène D; Hasel N; Kaghad M; Ferran E; Lupker J; Ferrara P
    Mol Inform; 2013 Feb; 32(2):213-29. PubMed ID: 27481282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.